Skip to main content

Table 1 Patient characteristics in the gefitinib and erlotinib groups

From: Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer

Characteristics Gefitinib (n = 232) Erlotinib (n = 86) p value
Median age (Range) 67 (24–90) 66 (34–90) 0.36
< 70 139 57  
≥ 70 93 29
Gender    0.90
Male 105 38  
Female 127 48
Histology    0.32
Adenocarcinoma 223 80  
Squamous cell carcinoma 8 5
Other 1 1
Smoking status    0.38
Ever smoker 130 43  
Never smoker 102 43
ECOG performance status    0.001
0 30 11  
1 143 68  
≥ 2 59 7
EGFR mutation status    < 0.001
Positive 91 53  
Negative 4 22
Unknown 137 11
Stage    0.75
≤ IIIB 48 16  
IV 184 70
CYP2D6 activity    0.42
functional 156 64  
reduced 50 16
unknown 26 6
HBs antigen    1.00
Positive 2 0  
Negative 211 85
Unknown 2 1
HCV antibody    0.10
Positive 15 5  
Negative 200 80
Unknown 17 1
Pretreatment LFT    0.42
normal 155 62  
abnormal 77 24  
  1. *Fisher’s exact test were applied to compare patient characteristics.
  2. ECOG, Eastern Cooperative Oncology Group; EGFR, Epidermal Growth Factor Receptor; HCV, hepatitis C virus; HBs, hepatitis B surface; LFT, liver function test; CYP2D6, cytochrome P450 2D6.